Revvity, Inc. announced that its Revvity Signals Software business is launching Signals BioDesign™, a cloud-native molecular cloning solution that streamlines biopharmaceutical research workflows. Built for biotech and pharmaceutical R&D teams, this platform simplifies complex cloning processes and enables scalable collaborative development in a unified digital environment. Combining essential cloning techniques with enterprise-grade collaboration addresses the limitations of desktop tools and overly complex platforms.
Signals BioDesign products provide a complete solution for designing therapeutic constructs across core cloning workflows such as Golden Gate, Gibson assembly, and restriction/ligation, as well as primer design, Sanger sequence analysis, and protein translation in one easy-to-use application. The solution enables high-throughput combinatorial cloning of up to 1,000 constructs while maintaining workflow simplicity, enabling pharmaceutical and biotech researchers to design faster, collaborate seamlessly, and eliminate costly data silos. As the only cloud-native molecular cloning tool integrated into the Signals One™ platform, the Signals BioDesign solution connects existing bioregistration and multimodal experiment capture and design in an integrated biopharmaceutical research ecosystem.
Signals BioDesign products address the critical needs of molecular biology teams developing the next generation of antibody, cell, and gene therapies. This solution enables researchers to eliminate the complexity of over-engineered platforms for enterprise-ready collaboration and centralized construction management. By integrating directly with the Signals One platform, we are focused on enabling teams to accelerate therapeutic development timelines and bring life-saving treatments to patients faster. ”
Kevin Willoe, President, Revvity Signals Software
Cloud-native architecture enables real-time team collaboration, centralized biosequencing libraries, duplicate checking, monomer management, and granular access controls that desktop tools cannot provide, and multi-tenant SaaS deployments eliminate administrative overhead and compliance risks associated with desktop software licenses. The Signals BioDesign solution’s AI-enabled data infrastructure positions research teams for future machine learning applications in sequence optimization and predictive design.
Revvity will introduce Signals BioDesign products at the Bio-IT World Conference & Expo, May 19-21 in Boston, Massachusetts.
sauce:
Revvity Signals Software Inc.
